Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Ewing

Surgery Corpus Christi, TX Medical Doctor

NPI 1053708784 CMS profile 7673219

6133 Parkway Dr, Corpus Christi, TX 78414

Open in the dashboard

General payments

$450,243

700 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Ewing of Corpus Christi, TX is reported in the CMS Open Payments database as having received $450,243 across 700 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $190,213 270
2024 General $108,547 165
2023 General $50,160 86
2022 General $81,920 107
2021 General $19,151 69
2020 General $191 2
2019 General $62 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Ewing
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Michael Ewing were reported at $190,213. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Michael Ewing Surgery median Middle half National median
2019 $62 $253 $82–$1,521 $163
2020 $191 $131 $40–$706 $114
2021 $19,151 $168 $50–$904 $132
2022 $81,920 $224 $76–$1,218 $149
2023 $50,160 $253 $82–$1,255 $160
2024 $108,547 $279 $90–$1,381 $164
2025 $190,213 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $417,587 564 payments
  2. Integra LifeSciences Corporation $26,005 80 payments
  3. Davol Inc. $2,338 17 payments
  4. Medical Device Business Services, Inc. $1,362 6 payments
  5. Stryker Corporation $1,209 3 payments
  6. Ethicon US, LLC $535 11 payments
  7. TELA Bio, Inc. $331 4 payments
  8. Kerecis Limited $233 1 payment
  9. Boston Scientific Corporation $204 2 payments
  10. Medtronic, Inc. $165 3 payments
  11. Other $275 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $289,521 96 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $65,900 55 payments
  3. Travel and Lodging $47,602 196 payments
  4. Food and Beverage $28,695 338 payments
  5. Consulting Fee $18,360 10 payments
  6. Gift $165 5 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $400,796 553 payments
  2. DA VINCI SP $16,792 11 payments
  3. Integra Recon-Skin And Wound $13,207 42 payments
  4. OMNIGRAFT $8,325 33 payments
  5. Integra Recon-Skin And Wound $6,307 38 payments
  6. ADVANCED WOUND CARE $6,120 3 payments
  7. PRIMATRIX $5,135 11 payments
  8. DuraSorb Monofilament Mesh $5,000 2 payments
  9. INTEGRA DERMAL REGENERATION TEMPLATE $2,821 38 payments
  10. SURGIMEND $2,616 54 payments
  11. Other $8,515 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

1,072

Median for General Surgery: 59

Drug cost

$3,168

Median for General Surgery: $393

Branded share of claims

43.8%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Odt Ondansetron Brand 231 $1,011
Celecoxib Generic 147 $531
Scopolamine Generic 38 $506
Acetaminophen-Codeine Acetaminophen With Codeine Brand 227 $402
Gabapentin Generic 172 $285
Tramadol Hcl Generic 180 $202
Cyclobenzaprine Hcl Generic 53 $104
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $70
Pantoprazole Sodium Generic 13 $57

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$74,624

Medicare's payments for the services billed

Medicare patients

147

Average age 73

Services billed

303

76 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 42%
Chronic kidney disease 29%
Ischemic heart disease 28%
Depression 25%
Cancer 24%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

700 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record